{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T07:33:58Z","timestamp":1758353638952,"version":"3.44.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04808-2","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T08:45:28Z","timestamp":1758271528000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population pharmacokinetic analysis of fluorouracil and oxaliplatin in the absence or presence of zolbetuximab in locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma"],"prefix":"10.1007","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7527-1897","authenticated-orcid":false,"given":"Akihiro","family":"Yamada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianning","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter L.","family":"Bonate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nakyo","family":"Heo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivasu","family":"Poondru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"4808_CR1","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/s0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA et al (2023) Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401:1655\u20131668. https:\/\/doi.org\/10.1016\/s0140-6736(23)00620-7","journal-title":"Lancet"},{"key":"4808_CR2","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D et al (2023) Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med 29:2133\u20132141. https:\/\/doi.org\/10.1038\/s41591-023-02465-7","journal-title":"Nat Med"},{"key":"4808_CR3","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","volume":"32","author":"U Sahin","year":"2021","unstructured":"Sahin U, T\u00fcreci \u00d6, Manikhas G, Lordick F, Rusyn A, Vynnychenko I et al (2021) FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol 32:609\u2013619. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.005","journal-title":"Ann Oncol"},{"key":"4808_CR4","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1158\/1078-0432.ccr-23-0204","volume":"29","author":"SJ Klempner","year":"2023","unstructured":"Klempner SJ, Lee KW, Shitara K, Metges JP, Lonardi S, Ilson DH et al (2023) ILUSTRO: phase II multicohort trial of zolbetuximab in patients with advanced or metastatic claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma. Clin Cancer Res 29:3882\u20133891. https:\/\/doi.org\/10.1158\/1078-0432.ccr-23-0204","journal-title":"Clin Cancer Res"},{"issue":"suppl 2","key":"4808_CR5","doi-asserted-by":"publisher","first-page":"S934","DOI":"10.1016\/j.annonc.2024.08.1595","volume":"35","author":"W Park","year":"2024","unstructured":"Park W, O\u2019Reilly EM, Li CP, Oh DY, Garcia-Carbonero R, Roth G et al (2024) Zolbetuximab with gemcitabine\u2009+\u2009nab-paclitaxel (GN) in first-line treatment of claudin 18.2\u2013positive metastatic pancreatic cancer (mPC): phase II, open-label, randomized study [abstract 1532TiP]. Ann Oncol 35(suppl 2):S934. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.1595","journal-title":"Ann Oncol"},{"key":"4808_CR6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s002800050980","volume":"44","author":"F Bressolle","year":"1999","unstructured":"Bressolle F, Joulia JM, Pinguet F, Ychou M, Astre C, Duffour J et al (1999) Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 44:295\u2013302. https:\/\/doi.org\/10.1007\/s002800050980","journal-title":"Cancer Chemother Pharmacol"},{"key":"4808_CR7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1067\/mcp.2000.109352","volume":"68","author":"C Terret","year":"2000","unstructured":"Terret C, Erdociain E, Guimbaud R, Boisdron-Celle M, McLeod HL, F\u00e9ty-Deporte R et al (2000) Dose and time dependencies of 5-fluorouracil pharmacokinetics. Clin Pharmacol Ther 68:270\u2013279. https:\/\/doi.org\/10.1067\/mcp.2000.109352","journal-title":"Clin Pharmacol Ther"},{"key":"4808_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1191\/1078155204jp129oa","volume":"10","author":"B Porta-Oltra","year":"2004","unstructured":"Porta-Oltra B, P\u00e9rez-Ruixo JJ, Climente-Mart\u00ed M, Merino-Sanju\u00e1n M, Almenar-Cubells D, Jim\u00e9nez-Torres NV (2004) Population pharmacokinetics of 5-fluorouracil in colorectal cancer patients. J Oncol Pharm Pract 10:155\u2013167. https:\/\/doi.org\/10.1191\/1078155204jp129oa","journal-title":"J Oncol Pharm Pract"},{"key":"4808_CR9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/bf03257473","volume":"51","author":"ABP van Kuilenburg","year":"2012","unstructured":"van Kuilenburg ABP, H\u00e4usler P, Schalhorn A, Tanck MWT, Proost JH, Terborg C et al (2012) Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy. Clin Pharmacokinet 51:163\u2013174. https:\/\/doi.org\/10.1007\/bf03257473","journal-title":"Clin Pharmacokinet"},{"key":"4808_CR10","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.2174\/156802612803531414","volume":"12","author":"C Woloch","year":"2012","unstructured":"Woloch C, Di Paolo A, Marouani H, Bocci G, Ciccolini J, Lacarelle B et al (2012) Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity. Curr Top Med Chem 12:1713\u20131719. https:\/\/doi.org\/10.2174\/156802612803531414","journal-title":"Curr Top Med Chem"},{"key":"4808_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00280-012-2018-4","volume":"71","author":"F Mueller","year":"2013","unstructured":"Mueller F, B\u00fcchel B, K\u00f6berle D, Sch\u00fcrch S, Pfister B, Kr\u00e4henb\u00fchl S et al (2013) Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. Cancer Chemother Pharmacol 71:361\u2013370. https:\/\/doi.org\/10.1007\/s00280-012-2018-4","journal-title":"Cancer Chemother Pharmacol"},{"key":"4808_CR12","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1097\/00001813-200311000-00007","volume":"14","author":"G Bastian","year":"2003","unstructured":"Bastian G, Barrail A, Urien S (2003) Population pharmacokinetics of oxaliplatin in patients with metastatic cancer. Anti-Cancer Drugs 14:817\u2013824. https:\/\/doi.org\/10.1097\/00001813-200311000-00007","journal-title":"Anti-Cancer Drugs"},{"key":"4808_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00280-002-0550-3","volume":"51","author":"JP Delord","year":"2003","unstructured":"Delord JP, Umlil A, Guimbaud R, Gr\u00e9goire N, Lafont T, Canal P et al (2003) Population pharmacokinetics of oxaliplatin. Cancer Chemother Pharmacol 51:127\u2013131. https:\/\/doi.org\/10.1007\/s00280-002-0550-3","journal-title":"Cancer Chemother Pharmacol"},{"key":"4808_CR14","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1002\/cncr.22241","volume":"107","author":"M Fouladi","year":"2006","unstructured":"Fouladi M, Blaney SM, Poussaint TY, Freeman BB III, McLendon R, Fuller C et al (2006) Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a Pediatric Brain Tumor Consortium study. Cancer 107:2291\u20132297. https:\/\/doi.org\/10.1002\/cncr.22241","journal-title":"Cancer"},{"key":"4808_CR15","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/01.ftd.0000191305.64775.04","volume":"28","author":"Y Kho","year":"2006","unstructured":"Kho Y, Jansman FGA, Prins NH, Neef C, Brouwers JRBJ (2006) Population pharmacokinetics of oxaliplatin (85 mg\/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer. Ther Drug Monit 28:206\u2013211. https:\/\/doi.org\/10.1097\/01.ftd.0000191305.64775.04","journal-title":"Ther Drug Monit"},{"key":"4808_CR16","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/pbc.22544","volume":"55","author":"O Beaty","year":"2010","unstructured":"Beaty O III, Berg S, Blaney S, Malogolowkin M, Krailo M, Knight R et al (2010) A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children\u2019s Oncology Group study. Pediatr Blood Cancer 55:440\u2013445. https:\/\/doi.org\/10.1002\/pbc.22544","journal-title":"Pediatr Blood Cancer"},{"key":"4808_CR17","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00280-014-2667-6","volume":"75","author":"M Nikanjam","year":"2015","unstructured":"Nikanjam M, Stewart CF, Takimoto CH, Synold TW, Beaty O, Fouladi M et al (2015) Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing. Cancer Chemother Pharmacol 75:495\u2013503. https:\/\/doi.org\/10.1007\/s00280-014-2667-6","journal-title":"Cancer Chemother Pharmacol"},{"key":"4808_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13:143\u2013151. https:\/\/doi.org\/10.1208\/s12248-011-9255-z","journal-title":"AAPS J"},{"key":"4808_CR19","volume-title":"Introduction to linear regression analysis","author":"DC Montgomery","year":"2012","unstructured":"Montgomery DC, Peck EA, Vining GG (2012) Introduction to linear regression analysis, 5th edn. Wiley, Hoboken, NJ","edition":"5"},{"key":"4808_CR20","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00228-020-03060-2","volume":"77","author":"P Courlet","year":"2021","unstructured":"Courlet P, Guidi M, Alves Saldanha S, Cavassini M, Stoeckle M, Buclin T et al (2021) Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs. Eur J Clin Pharmacol 77:979\u2013987. https:\/\/doi.org\/10.1007\/s00228-020-03060-2","journal-title":"Eur J Clin Pharmacol"},{"key":"4808_CR21","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00280-014-2445-5","volume":"73","author":"M Darwish","year":"2014","unstructured":"Darwish M, Burke JM, Hellriegel E, Robertson P Jr, Phillips L, Ludwig E et al (2014) An evaluation of the potential for drug\u2013drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Chemother Pharmacol 73:1119\u20131127. https:\/\/doi.org\/10.1007\/s00280-014-2445-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"4808_CR22","doi-asserted-by":"publisher","first-page":"e236","DOI":"10.1371\/journal.pntd.0000236","volume":"2","author":"A El-Tahtawy","year":"2008","unstructured":"El-Tahtawy A, Glue P, Andrews EN, Mardekian J, Amsden GW, Knirsch CA (2008) The effect of azithromycin on ivermectin pharmacokinetics\u2014a population pharmacokinetic model analysis. PLoS Negl Trop Dis 2:e236. https:\/\/doi.org\/10.1371\/journal.pntd.0000236","journal-title":"PLoS Negl Trop Dis"},{"key":"4808_CR23","doi-asserted-by":"publisher","first-page":"545","DOI":"10.4196\/kjpp.2021.25.6.545","volume":"25","author":"Y Hong","year":"2021","unstructured":"Hong Y, Jeon S, Choi S, Han S, Park M, Han S (2021) An experience on the model-based evaluation of pharmacokinetic drug-drug interaction for a long half-life drug. Korean J Physiol Pharmacol 25:545\u2013553. https:\/\/doi.org\/10.4196\/kjpp.2021.25.6.545","journal-title":"Korean J Physiol Pharmacol"},{"key":"4808_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00280-018-3722-5","volume":"83","author":"L Deyme","year":"2019","unstructured":"Deyme L, Barbolosi D, Gattacceca F (2019) Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters. Cancer Chemother Pharmacol 83:27\u201342. https:\/\/doi.org\/10.1007\/s00280-018-3722-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"4808_CR25","first-page":"1205","volume":"6","author":"MA Graham","year":"2000","unstructured":"Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E (2000) Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 6:1205\u20131218","journal-title":"Clin Cancer Res"},{"key":"4808_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2024.107535","volume":"128","author":"X Wen","year":"2024","unstructured":"Wen X, Doherty C, Thompson LE, Kim C, Buckley BS, Jaimes EA et al (2024) Determination of unbound platinum concentrations in human plasma using ultrafiltration and precipitation methods. J Pharmacol Toxicol Methods 128:107535. https:\/\/doi.org\/10.1016\/j.vascn.2024.107535","journal-title":"J Pharmacol Toxicol Methods"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04808-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04808-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04808-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T08:45:29Z","timestamp":1758271529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04808-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4808"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04808-2","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"9 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.Y., J.Y., P.L.B., N.H., and S.P. are employees of Astellas.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The ILUSTRO study was conducted in accordance with the Declaration of Helsinki, Council for International Organizations of Medical Sciences International Ethical Guidelines, and International Council for Harmonisation Good Clinical Practice Guideline and received approval from an institutional review board. Written informed consent was provided by all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"89"}}